$14.41
4.27% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US29082K1051
Symbol
EMBC

Embecta Stock price

$14.41
+0.51 3.67% 1M
+1.28 9.75% 6M
-4.52 23.88% YTD
-2.97 17.09% 1Y
-32.59 69.34% 3Y
-32.59 69.34% 5Y
-32.59 69.34% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.59 4.27%
ISIN
US29082K1051
Symbol
EMBC
Sector

Key metrics

Market capitalization $831.48m
Enterprise Value $2.20b
P/E (TTM) P/E ratio 11.94
EV/FCF (TTM) EV/FCF 160.76
EV/Sales (TTM) EV/Sales 1.97
P/S ratio (TTM) P/S ratio 0.74
P/B ratio (TTM) P/B ratio negative
Dividend yield 4.16%
Last dividend (FY24) $0.60
Revenue growth (TTM) Revenue growth 0.48%
Revenue (TTM) Revenue $1.12b
EBIT (operating result TTM) EBIT $258.80m
Free Cash Flow (TTM) Free Cash Flow $13.70m
Cash position $281.80m
EPS (TTM) EPS $1.21
P/E forward 10.03
P/S forward 0.75
EV/Sales forward 1.98
Short interest 4.31%
Show more

Is Embecta a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Embecta Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Embecta forecast:

3x Hold
60%
2x Sell
40%

Analyst Opinions

5 Analysts have issued a Embecta forecast:

Hold
60%
Sell
40%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,119 1,119
0% 0%
100%
- Direct Costs 379 379
3% 3%
34%
740 740
1% 1%
66%
- Selling and Administrative Expenses 359 359
5% 5%
32%
- Research and Development Expense 83 83
5% 5%
7%
299 299
3% 3%
27%
- Depreciation and Amortization 40 40
29% 29%
4%
EBIT (Operating Income) EBIT 259 259
0% 0%
23%
Net Profit 70 70
48% 48%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Embecta directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Embecta Stock News

Neutral
GlobeNewsWire
about one hour ago
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024.
Neutral
GlobeNewsWire
about 2 hours ago
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024.
Neutral
GlobeNewsWire
14 days ago
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) ...
More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,200
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today